The stock of Cryolife Inc (NYSE:CRY) hit a new 52-week high and has $26.22 target or 38.00% above today’s $19.00 share price. The 8 months bullish chart indicates low risk for the $647.17M company. The 1-year high was reported on Nov, 11 by Barchart.com. If the $26.22 price target is reached, the company will be worth $245.92M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 167,080 shares traded hands. Cryolife Inc (NYSE:CRY) has risen 67.74% since April 11, 2016 and is uptrending. It has outperformed by 61.59% the S&P500.
Cryolife Inc (NYSE:CRY) Ratings Coverage
Out of 2 analysts covering Cryolife (NYSE:CRY), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cryolife has been the topic of 2 analyst reports since April 13, 2016 according to StockzIntelligence Inc. Lake Street initiated Cryolife Inc (NYSE:CRY) on Wednesday, June 15 with “Buy” rating. The firm earned “Buy” rating on Wednesday, April 13 by Canaccord Genuity.
According to Zacks Investment Research, “CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The company’s BioGlue surgical adhesive, the company marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The company also manufactures CryoLife- O’Brien and CryoLife-Ross stentless porcine heart valves which are distributed within the European Community. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 2.19 in Q2 2016. Its up 0.45, from 1.74 in 2016Q1. The ratio is positive, as 8 funds sold all Cryolife Inc shares owned while 24 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 19.57 million shares or 9.07% more from 17.94 million shares in 2016Q1.
Citadel Advsrs, a Illinois-based fund reported 14,626 shares. Louisiana State Employees Retirement Systems accumulated 0.01% or 11,400 shares. Jpmorgan Chase & Company holds 0% or 2,499 shares in its portfolio. Chicago Equity Prtnrs Ltd Co last reported 59,810 shares in the company. Perritt Cap Management has 0.56% invested in the company for 179,240 shares. Health Value Capital Limited Liability Company last reported 5.73% of its portfolio in the stock. Ameriprise accumulated 0% or 145,061 shares. Rhumbline Advisers last reported 0% of its portfolio in the stock. Credit Suisse Ag accumulated 41,141 shares or 0% of the stock. Alliancebernstein Limited Partnership last reported 0% of its portfolio in the stock. Thrivent Financial For Lutherans has 0% invested in the company for 12,470 shares. Essex Lc holds 0.15% of its portfolio in Cryolife Inc (NYSE:CRY) for 77,961 shares. State Board Of Administration Of Florida Retirement holds 0% or 46,069 shares in its portfolio. Bridgeway Cap Management Incorporated has invested 0.02% of its portfolio in Cryolife Inc (NYSE:CRY). Fincl Bank Of America Corporation De accumulated 0% or 22,484 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 2 insider sales for $143,600 net activity. 10,000 Cryolife Inc (NYSE:CRY) shares with value of $115,600 were sold by McCall Ronald D. RONALD C ELKINS had sold 2,000 shares worth $28,000.
More notable recent Cryolife Inc (NYSE:CRY) news were published by: Fool.com which released: “Why Cryolife Inc’s Shares Turned Hot Today” on July 26, 2016, also Prnewswire.com with their article: “CryoLife Announces Definitive Agreement to Acquire On-X Life Technologies …” published on December 22, 2015, Prnewswire.com published: “CryoLife Announces Release Date and Teleconference Call Details for 2016 Third …” on October 12, 2016. More interesting news about Cryolife Inc (NYSE:CRY) were released by: Prnewswire.com and their article: “James W. Bullock Joins CryoLife Board of Directors” published on October 25, 2016 as well as Prnewswire.com‘s news article titled: “CryoLife to Present at Morgan Stanley Global Healthcare Conference” with publication date: September 07, 2016.
CRY Company Profile
CryoLife, Inc. (CryoLife), incorporated on January 19, 1984, is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Firm operates in two divisions: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.